Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China

Lorlatinib has shown remarkable efficacy in both first-line and subsequent-line treatment settings for patients with locally advanced or metastatic ALK ⁺ NSCLC. Effective management of lorlatinib-related adverse events, through close monitoring and timely intervention, is essential to enhance patient tolerance. Lorlatinib has progressively transformed the therapeutic landscape for patients with ALK ⁺ NSCLC.